IP Library › Granted Patent US 9,387,212
Granted Patent B2
US 9,387,212 · App. 14/395,533 · Granted Jul 12, 2016

Methods for treating Parkinson's disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,387,212
App. No.
14/395,533
Granted
Jul 12, 2016
Kind
B2
Abstract

The invention pertains to a method of treating Parkinson's disease (PD) in a mammal, comprising administering a first pharmaceutical agent and a second pharmaceutical agent, wherein the first pharmaceutical agent is an antagonist of the adenosine receptor 2 (A 2A ) and the second pharmaceutical agent is an antagonist of the N-methyl-D-aspartate (NMDA) receptor subtype NR2B.

Claims (15)

1. A pharmaceutical composition comprising a therapeutically effective amount of a combination of the pharmaceutical agents 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide (TOZADENANT®) and 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide (Radiprodil) in a pharmaceutical acceptable carrier.

2. A kit comprising

(a) a first container containing 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methylpiperidine-1-carboxamide (TOZADENANT®)

and

(b) a second container containing 2-[4-[(4-fluorophenyl)methyl]piperidin-1-yl]-2-oxo-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide (Radiprodil).

3. The composition according to claim 1 wherein the ratio of TOZADENANT® to Radiprodil is from 30:1 to 1:30 by weight.

4. The kit according to claim 2 wherein the ratio of TOZADENANT® to Radiprodil is from 30:1 to 1:30 by weight.

5. The composition according to claim 1 wherein the ratio of TOZADENANT® to Radiprodil is from 10:1 to 1:10 by weight.

6. The composition according to claim 1 wherein the ratio of TOZADENANT® to Radiprodil is from 3:1 to 1:3 by weight.

7. The kit according to claim 2 wherein the ratio of TOZADENANT® to Radiprodil is from 10:1 to 1:10 by weight.

8. The kit according to claim 2 wherein the ratio of TOZADENANT® to Radiprodil is from 3:1 to 1:3 by weight.

9. The composition according to claim 1 in the form of a tablet.

10. The composition according to claim 3 in the form of a tablet.

11. The composition according to claim 5 in the form of a tablet.

12. The composition according to claim 6 in the form of a tablet.

Assignments (2)
CONFIRMATORY ASSIGNMENT Recorded Jun 10, 2016
From: UCB PHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 038953/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2015
From: MICHEL, ANNE; DOWNEY, PATRICK; MONTEL, FLORIAN; SCHELLER, DIETER; CHRISTOPHE, BERNARD
To: UCB PHARMA, S.A.
Reel/Frame 034713/0820 →